New drug shows promise in early trial for serious fatty liver disease
NCT ID NCT06297434
Summary
This study tested a new drug called J2H-1702 for people with non-alcoholic steatohepatitis (NASH), a serious form of fatty liver disease. 87 participants received either one of three doses of the drug or a placebo for 12 weeks. The main goals were to check the drug's safety and see if it could reduce liver fat and scarring.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-ALCOHOLIC STEATOHEPATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
J2H Biotech
Suwon, Gyeonggi-do, 16684, South Korea
Conditions
Explore the condition pages connected to this study.